TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Aug 29, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help children who experience bleeding after having their tonsils removed, a procedure called a tonsillectomy. Sometimes, after this surgery, kids may bleed, which can be a serious issue. The researchers want to see if a special mist medicine called nebulized tranexamic acid (TXA) can stop the bleeding effectively without needing to do any additional surgery. If successful, this treatment could help children recover better and avoid the risks and fears that come with more surgeries.

To participate in this trial, children must be between the ages of 2 and 17 and have experienced bleeding after their tonsillectomy at least 24 hours after the surgery. However, kids with certain medical conditions, such as bleeding disorders or allergies to the medicine being tested, won't be eligible. The trial is currently not recruiting participants, but when it begins, families can expect to see how this mist treatment can help their child recover from tonsil surgery complications without needing more invasive procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Received a tonsillectomy
• • 2. Presents to the ED with secondary\* post-tonsillectomy hemorrhage
• • 3. Children between age of 2 to 17 years of age (i.e., before their 18th birthday) \*Secondary post-tonsillectomy hemorrhage is defined as greater than 24 hours from their primary tonsillectomy operation (arrival in recovery/PACU).
• Exclusion Criteria:
• • 1. Known and documented bleeding or clotting disorder.
• • 2. Known pregnancy.
• • 3. Patients with known hypersensitivity or allergic response to tranexamic acid.
• • 4. Parents or guardians who cannot communicate in English or Spanish.
• • 5. Intubation prior to enrollment.
• • 6. Previously enrolled patients.